Product Overview
Compounded Injectable Tirzepatide is a dual GLP-1 and GIP receptor agonist formulated for subcutaneous injection. It is intended to support appetite regulation and metabolic processes under medical supervision.
How It Works
Tirzepatide activates both the GLP-1 and GIP receptors. This dual mechanism supports appetite control, glucose-dependent insulin secretion, and metabolic regulation.
Safety Information
Do not use if you have:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Consult a healthcare provider before use if you have:
- A history of pancreatitis
- Gallbladder disease
- Kidney disease or dehydration
- Severe gastrointestinal disorders
- Diabetic retinopathy
- A history of thyroid disease
GLP-1–based therapies have shown thyroid C-cell tumors in animal studies. Human relevance is unknown.
Risk of hypoglycemia may increase when used with insulin or insulin secretagogues.
Common Side Effects
Commonly reported side effects may include:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Decreased appetite
Fatigue
Headache
Dizziness
Serious adverse reactions may include pancreatitis, gallbladder disease, kidney injury, or severe gastrointestinal symptoms.
Compounding Disclosure
This medication is compounded by a licensed pharmacy and is not FDA-approved. Compounded medications are prepared based on a healthcare provider’s prescription.